Please use this identifier to cite or link to this item:
Title: Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination.
Austin Authors: Dang, Yew Li;Bryson, Alexander 
Affiliation: Neurology
Department of Neurology, Box Hill Hospital, Box Hill, Victoria, Australia
Issue Date: 30-Nov-2021
Date: 2021-11-30
Publication information: BMJ Case Reports 2021; 14(11): e246701
Abstract: We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2 weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. Although some features of the patient's presentation were typical of recently reported cases of a rare GBS variant post-Oxford-AstraZeneca vaccination, including severe facial weakness and a lack of respiratory involvement, to our knowledge this is the first reported case of MFS associated with SARS-CoV2 vaccination. While postvaccination GBS remains rare, it appears to have a favourable prognosis, and recognising this entity is therefore important for patient counselling and monitoring for potential complications.
DOI: 10.1136/bcr-2021-246701
ORCID: 0000-0002-0570-5398
Journal: BMJ Case Reports
PubMed URL: 34848426
Type: Journal Article
Subjects: COVID-19
cranial nerves
peripheral nerve disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 17, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.